Developer docs
API playgroundTry for free, no card

Search company profiles

Micron Medical

Full company profile

uuid0009j1z

Namestring
Micron Medical
Websiteurl
micronmed.com
Company typeenum
Private
Founded yearint
2019
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoca Raton, United States
HQ citystring
Boca Raton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
wireless neuromodulation devices, sacral neuromodulation therapy, overactive bladder treatment, bladder dysfunction devices, implantable medical devices
Industry2 codes
1Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
CodeHLAHAEAKPrimaryYes
2Neurourology & Voiding Dysfunction
CodeHLAKAOAIPrimaryNo
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neuromodulation Medical Devices
Social media profiles2 records
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Micron Medical is developing an investigational wireless sacral neuromodulation device for the treatment of overactive bladder (OAB) and other bladder dysfunctions. The device uses mid-field inductive wireless power transfer technology, removing the need for implanted batteries that are a major drawback of traditional sacral neuromodulation therapy (FDA-approved in 1997). The product targets urology and urogynecology healthcare providers and their patients with bladder dysfunction.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Wireless Sacral Neuromodulation Device (Investigational)
CategoryNeuromodulation Medical Devices
Description

An investigational medical device that delivers sacral neuromodulation therapy to treat overactive bladder (OAB) and other bladder dysfunctions without the need for implanted batteries, using mid-field inductive wireless power transfer technology. It is intended for healthcare providers and facilities in urology and urogynecology treating patients who require neuromodulation therapy for bladder control.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers8 records
1Axonics
TypeDirect peer
Description

Direct competitor developing rechargeable and recharge-free sacral neuromodulation systems for OAB and fecal incontinence; competes head-to-head with Micron in the same indication, customer base, and FDA pathway.

2Medtronic
TypeBroad incumbent
Description

Developer of InterStim, the FDA-approved (1997) sacral neuromodulation system that established the SNM category. Medtronic is the dominant incumbent in urologic neuromodulation with deep physician relationships and global commercial infrastructure.

3Boston Scientific
TypeBroad incumbent
Description

Major neuromodulation incumbent with the Precision Spectra and WaveWriter portfolios spanning SCS and DBS; an active acquirer of urology and pelvic health assets, making it both a competitor and likely strategic acquirer.

4Abbott
TypeBroad incumbent
Description

Holds the Proclaim DRG and Proclaim Elite neuromodulation systems following the St. Jude acquisition; broader neuromodulation and urology portfolio overlapping with Micron's therapy area.

5Nevro
TypeBroad incumbent
Description

Developer of the Senza and HFX 10 kHz spinal cord stimulation systems; adjacent neuromodulation technology player pursuing similar implantable, electrically powered therapy modalities with overlapping regulatory and engineering expertise.

6Laborie Medical Technologies
TypeEmerging player
Description

Urology-focused medical device company with diagnostic and therapeutic urology offerings including neuromodulation assets (e.g., Cogentix); competes in the same physician call point and is a plausible strategic acquirer.

7CVRx
TypeEmerging player
Description

Developer of the Barostim implantable neuromodulation system for heart failure; comparable as an early-commercial-stage neuromodulation device company using implanted pulse generators without battery-replacement surgery in some architectures.

8Nalu Medical
TypeEmerging player
Description

Developer of a small, battery-free peripheral nerve stimulation system using an external wearable pulse generator; comparable wireless/battery-free architecture with overlapping miniaturized implantable neuromodulation engineering challenges.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Micron Medical

Neuromodulation Medical Devicesmicronmed.com

Micron Medical firmographics

Firmographics
Name
Micron Medical
Website
https://micronmed.com
Company type
Private
Founded year
2019
Headcount range
11–50 employees
Ownership category
akta.pro rank

Micron Medical industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)
akta.pro secondary industry
Neurourology & Voiding Dysfunction (HLAKAOAI)

Keywords

  • Wireless neuromodulation devices
  • Sacral neuromodulation therapy
  • Overactive bladder treatment
  • Bladder dysfunction devices
  • Implantable medical devices

Where Micron Medical is headquartered

Location

Headquarters

HQ city
Boca Raton
HQ country
United States
HQ region
North America

Markets served

Micron Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Micron Medical product offering

Product offering

Core offering

Micron Medical is developing an investigational wireless sacral neuromodulation device for the treatment of overactive bladder (OAB) and other bladder dysfunctions. The device uses mid-field inductive wireless power transfer technology, removing the need for implanted batteries that are a major drawback of traditional sacral neuromodulation therapy (FDA-approved in 1997). The product targets urology and urogynecology healthcare providers and their patients with bladder dysfunction.

Differentiator

Problem solved

Functional benefit

Products and services

  • Wireless Sacral Neuromodulation Device (Investigational) An investigational medical device that delivers sacral neuromodulation therapy to treat overactive bladder (OAB) and other bladder dysfunctions without the need for implanted batteries, using mid-field inductive wireless power transfer technology. It is intended for healthcare providers and facilities in urology and urogynecology treating patients who require neuromodulation therapy for bladder control.

Companies that use Micron Medical

Customer profile

Segments1 record

Ideal customer profiles1 record

Micron Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Micron Medical partnerships and signals

Strategic signal

Recent moves1 record

Micron Medical competitors and assessment

Company assessment

Direct peers

  • Axonics: Direct competitor developing rechargeable and recharge-free sacral neuromodulation systems for OAB and fecal incontinence; competes head-to-head with Micron in the same indication, customer base, and FDA pathway.

Broad incumbents

  • Medtronic: Developer of InterStim, the FDA-approved (1997) sacral neuromodulation system that established the SNM category. Medtronic is the dominant incumbent in urologic neuromodulation with deep physician relationships and global commercial infrastructure.
  • Boston Scientific: Major neuromodulation incumbent with the Precision Spectra and WaveWriter portfolios spanning SCS and DBS; an active acquirer of urology and pelvic health assets, making it both a competitor and likely strategic acquirer.
  • Abbott: Holds the Proclaim DRG and Proclaim Elite neuromodulation systems following the St. Jude acquisition; broader neuromodulation and urology portfolio overlapping with Micron's therapy area.
  • Nevro: Developer of the Senza and HFX 10 kHz spinal cord stimulation systems; adjacent neuromodulation technology player pursuing similar implantable, electrically powered therapy modalities with overlapping regulatory and engineering expertise.

Emerging players

  • Laborie Medical Technologies: Urology-focused medical device company with diagnostic and therapeutic urology offerings including neuromodulation assets (e.g., Cogentix); competes in the same physician call point and is a plausible strategic acquirer.
  • CVRx: Developer of the Barostim implantable neuromodulation system for heart failure; comparable as an early-commercial-stage neuromodulation device company using implanted pulse generators without battery-replacement surgery in some architectures.
  • Nalu Medical: Developer of a small, battery-free peripheral nerve stimulation system using an external wearable pulse generator; comparable wireless/battery-free architecture with overlapping miniaturized implantable neuromodulation engineering challenges.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Micron Medical social profiles

Digital presence

Micron Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Micron Medical leadership team

Management profile

Number of profiles

Micron Medical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Micron Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Micron Medical

What does Micron Medical do?

Micron Medical is developing an investigational wireless sacral neuromodulation device for the treatment of overactive bladder (OAB) and other bladder dysfunctions. The device uses mid-field inductive wireless power transfer technology, removing the need for implanted batteries that are a major drawback of traditional sacral neuromodulation therapy (FDA-approved in 1997). The product targets urology and urogynecology healthcare providers and their patients with bladder dysfunction.

When was Micron Medical founded?

Micron Medical was founded in 2019. It employs 11 to 50 people.

Where is Micron Medical based?

Micron Medical is headquartered in Boca Raton, United States, in the North America region.

Who are Micron Medical's main competitors?

Axonics is listed as a direct peer. Broad incumbents are Medtronic, Boston Scientific, Abbott and Nevro. Emerging players are Laborie Medical Technologies, CVRx and Nalu Medical.

Does Micron Medical have an API?

No public API is recorded for Micron Medical.

What industry is Micron Medical in?

Micron Medical's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAOAI, Neurourology & Voiding Dysfunction. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireUro Medical Corporation Acquires Micron Medical and Initiates the FDA IDE Approved “Guardian” RCT of the Protect PNS Injectable Tibial Stimulator for Treatment of Overactive BladderUro Medical Corporation acquired Micron Medical's urology assets and initiated the Guardian RCT for its Protect PNS injectable tibial stimulator. The trial compares tibial stimulation to medical management for overactive bladder, enrolling about 600 subjects. Results will support payor reimbursement and the company aims for FDA approval.GlobeNewswireMicron Medical Announces Sale of Peripheral Pain Nerve Stimulator Division (Moventis PNS) to Pain Specialists Group Ltd.Micron Medical sold its peripheral pain nerve stimulator division, Moventis PNS, to Pain Specialists Group Ltd. The sale completes its evolution into a urology-focused device company, with financial terms undisclosed. The company now focuses on FDA approval and U.S. launch of Protect PNS for overactive bladder.GlobeNewswireMicron Medical Hosting Key Opinion Leader Webinar on Protect PNS: A Percutaneous Wireless Micro-Neurostimulation Technology for Overactive Bladder December 9 at 11am ESTMicron Medical will host a KOL webinar on its Protect PNS system for overactive bladder on December 9, 2020, at 11am EST. The webinar features panelists Larry Sirls and Ken Peters, and CEO Mark Landy will discuss commercial plans. Protect PNS is expected to be commercially available in the U.S. in 2021 pending FDA classification.GlobeNewswireMicron Medical Appoints Seasoned Healthcare Executive Mark Landy as Chief Executive OfficerMicron Medical appointed Dr. Mark Landy as its new Chief Executive Officer and board member, effective immediately. The company is currently advancing the U.S. commercial launch of its MOVENTIS PNS device while preparing for the 2021 availability of its PROTECT PNS product pending FDA classification.GlobeNewswireMicron Medical Appoints Seasoned Urology Executive Matthew Kemp as Chief Commercial OfficerMicron Medical appointed Matthew Kemp as Chief Commercial Officer, with over 20 years of healthcare leadership experience. He will build the commercial organization to support Protect PNS, a tibial nerve stimulator for overactive bladder, expected commercially available in the U.S. in early 2021.GlobeNewswireLeading Urology KOLs Host Live Webinar Entitled “The Protect PNS for OAB: A Wireless Uro-Stimulation Injectable Technology” on April 29 at 5pm ETMicron Medical will host a webinar on April 29 at 5pm ET with urology experts to discuss its wireless uro-stimulation injectable technology for overactive bladder syndrome. The device delivers controlled electrical pulses to the tibial nerve via a fabric antenna. The webinar aims to present the current treatment landscape and unmet medical need.